BioInnovation Institute announces latest cohort of companies entering Venture Lab program

/in

BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces the latest cohort of participants in its Venture Lab acceleration program for early-stage companies. The eight ventures are strategically aligned with BII’s focus, developing ground-breaking scientific initiatives across three specialist areas – therapeutics, bioindustrials and health tech. Read more

Read more

Novo Nordisk Foundation, Open Philanthropy, and Bill & Melinda Gates Foundation Launch Initiative to Support New Antiviral Medicines for Future Pandemics

/in

COPENHAGEN – SAN FRANCISCO – SEATTLE. Today, the Novo Nordisk Foundation, Open Philanthropy, and the Bill & Melinda Gates Foundation announced an initial commitment of up to $90 million of coordinated funding toward Pandemic Antiviral Discovery (PAD), a new initiative to catalyze discovery and early development of antiviral medicines for future pandemics. With equitable access […]

Read more

Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting

/in

Combination antibiotics released from STIMULAN completely kill antibiotic resistant biofilms STIMULAN is the only calcium matrix antibiotic carrier approved for use in bone and soft tissue in the EU, UK, Canada, and Saudi Arabia Keele, UK, 15 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use […]

Read more

Gadeta announces significant progress in advancing pipeline and TEG platform development

/in

Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors Ph1/2 update on lead product GDT002 as well as nomination of second pipeline program GDT201 Utrecht, Netherlands and Boston, Mass., 15 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every cancer […]

Read more

James Brady Joins Verona Pharma as Non-Executive Director

/in

LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a Non-Executive Director. Read more…

Read more
© Optimum Strategic Communications.